Skip to main content
SpringerLink
Log in

Use of granulocyte-macrophage colony stimulating factor in the treatment of prolonged haematopoietic dysfunction after chemotherapy alone or chemotherapy plus bone marrow transplantation

  • Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

This study evaluates the use of granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with prolonged haematopoietic dysfunction (>21 days) after using chemotherapy to treat cancer. One hundred and seven patients were identified who had a leucocyte count below 1000 cells/mm3 more than 21 days after start of chemotherapy (81 patients) or after bone marrow transplantation (BMT) (26 patients). There were 66 males and 40 females ranging in age from 4.5 to 82 years. The duration of aplasia was 48 ± 43 days in the chemotherapy alone group, and 79 ± 57 days in the post BMT group. Over 80% of the patients had haematologic malignancies and 70% had an infection prior to the start of the cytokine. Patients received 5 μg GM-CSF/kg1 body weight daily i.v. or s.c. for 14 ± 11 days in the chemotherapy group and 20 ± 26 days in the BMT group. Sixty percent of chemotherapy patients and 58% of BMT patients had a haematological response to treatment (leucocyte count >2000 cells/mm3. Median times to haematologic recovery were 7 days in the chemotherapy group and 10 days in the BMT group. There was a significant reduction in the number of infections (73% to 28% in the chemotherapy group). Clinical responses in the two groups were 55% and 50%, respectively. No severe, drug-related adverse events were reported and no evidence of stimulation of malignant clones was observed. It is concluded that GM-CSF is effective and well tolerated in patients with prolonged bone marrow dysfunction after chemotherapy or BMT. Although results from an open-label trial must be viewed with caution, this observation confirms the value and safety of GM-CSF therapy in patients with this severe, and often fatal, condition.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nemunaitis, J., Singer, J.W., Duckner, C.D., Durnam, D., Epstein, C., Hill, R., Storb, R., Thomas, E.D. and Appelbaum, F.R. (1990) Use of Recombinant Human Granulocyte-Macrophage Colony — Stimulating Factor in Graft Failure after Bone Marrow Transplantation.Blood 76, 245–53.

    PubMed  CAS  Google Scholar 

  2. Weisdorf, D.J., Verfaillie, C.M., Davies, S.M., Filpovich, A.H, Wagner, J.E. Jr, Miller, J.S., Burroughs, J., Ramsay, M.K.C., Kersey, J.H., McGlave, P.B. and Blazer, B.R. (1995) Hematopoietic Growth Factors for Graft Failure after Bone Marrow Transplantation: A Randomized Trial of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Sequential GM-CSF Plus Granulo-cyte-CSF.Blood 85, 3452–6.

    PubMed  CAS  Google Scholar 

  3. Gorin, N.-C., Laporte, J.P. and Fouillard, L. (1995) Granulocyte-Macrophage Colony-Stimulating Factor as an Adjunct to Autologous Bone Marrow Transplantation in Hematology: Considerations on Increased Safety in the Transplant Ward. In N.I. Nissen and T.M. Dexter (eds)Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): Current Uses and Future Applications, pp. 38–45. Proc. Int. Symp. September 9–11, 1993. Cheshire: Pennine Press.

    Google Scholar 

  4. Sierra, J., Terol, M.J., Urbano-Isizua, A., Rovira, M., Marin, P., Carreras, E., Batlle, M. and Rozman, C. (1994) Different Responses to Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Primary and Secondary Graft Failure after Bone Marrow Transplantation.Exp. Hematol. 22, 566–72.

    PubMed  CAS  Google Scholar 

  5. Gerhartz, H.H., Engelhart, M., Meusers, P., Brittinger, G., Wilmanns, W., Scholimok, G., Mueller, P., Huhn, D., Musch, R., Siegert, W., Gerhatz, D., Hartlapp, J.H., Thiel, E., Huber, C., Peschl, C., Spann, W., Emmerich, B., Schadek, C., Westerhausen, M., Pees, H.W., Radtke, H., Engert, A., Terhardt, E., Schick, H., Binder, T., Fuchs, R., Hasford, J., Brandmeier, R., Stern, A., Jones, T.C., Ehrlich, F.J., Stein, H., Parwaresch, M., Tiemann, M. and Lennert, K. (1993) Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhGM-CSF) as Adjunct to Induction Treatment of High-Grade Malignant Non-Hodgkin’s Lymphomas.Blood 82, 2329–39.

    PubMed  CAS  Google Scholar 

  6. Nemunaitis, J., Rabinowe, S.N., Singer, J.W., Bierman, P.J., Vose, J.M., Freedman, A.S., Onetto, N., Gillis, S., Oette, D., Gold, M., Buckner, D., Hansen, J.A., Ritz, J., Appelbuaum, F.R., Armitage, J.O. and Nadler, I.M. (1991) Recombinant Granulocyte-Macrophage Colony-Stimulating Factor after Autologous Bone Marrow Transplantation for Lymphoid Cancer.New Engl. J. Med. 324, 1773–78.

    Article  PubMed  CAS  Google Scholar 

  7. Dreger, P., Suttorp, M., Haferlach, T., Loeffler, H., Schmitz, N. and Schroyens, W. (1993). Allogeneic Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood Progenitor Cells for Treatment of Engraftment Failure after Bone Marrow Transplantation.Blood 81, 1404–7.

    PubMed  CAS  Google Scholar 

  8. Vose, J.M., Bierman, P.J., Kessinger, A., Cocda, P.F., Anderson, J., Oldman, F.B., Epstein, C. and Armitage, J.O. (1991) The Use of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor for the Treatment of Delayed Engraftment Following High Dose Therapy and Autologous Stem Cell Transplantation for Lymphoid Malignancies.Bone Marr. Transpl. 7, 139–43.

    CAS  Google Scholar 

  9. Kingmann, H.-G., Eaves, A.C., Barnett, M.J., Reece, D.E., Shepherd, J.D., Belch, A.R., Brandwein, J.M., Langleben, A., Koch, P.A. and Phillips, G.L. (1990) Recombinant GM-CSF in Patients with Poor Graft Function after Bone Marrow Transplantation.Clin. Invest. Med. 13, 77–81.

    Google Scholar 

  10. Ippoliti, C., Przepiorka, D., Giralt, S., Andersson, B.S., Wallerstein, R.O., Gutterman, J., Deisseroth, A.B. and Champlin, R.E. (1993) Low-Dose Non-Glycosylated rhGM-CSF is Effective for the Treatment of Delayed Hematopoietic Recovery after Autologous Marrow or Peripheral Blood Stem Cell Transplantation.Bone Marr. Transpl. 11, 55–9.

    CAS  Google Scholar 

  11. Crump, M., Couture, F., Kovacs, M., Saragosa, R., McCrae, J., Brandwein, J., Huebsch, L., Beauregard-Zollinger, L. and Keating, A. (1993) Interleukin-3 Followed by GM-CSF for Delayed Engraftment after Autologous Bone Marrow Transplantation.Exp. Hematol. 21, 405–10.

    PubMed  CAS  Google Scholar 

  12. Bierman, P., Appelbaum, F., Oette, D., Gillis, S., Armitage, J. and Nemunaitis, J. (1992) Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Engraftment Failure (EF) Following Autologous (Auto) or Allogeneic (Allo) Bone Marrow Transplantation (BMT).Blood 80, 1065, 269a.

    Google Scholar 

  13. Rosenthal, N.S. and Farhi, D.C. (1994) Failure to Engraft after Bone Marrow Transplantation: Bone Marrow Morphologic Findings.Am. J. Clin. Pathol. 102, 821–4.

    PubMed  CAS  Google Scholar 

  14. Foucar, K. (1994) Bone Marrow Histiocytosis and Autologous Graft Failure: Possible Implications.Am. J. Clin. Pathol. 102, 713–4.

    PubMed  CAS  Google Scholar 

  15. Rowe, J.M., Andersen, J.W., Mazza, J.J., Bennett, J.M., Paietta, E., Hayes, F.A., Oette, D., Cassileth, P.A., Stadtmauer E.A. and Wiernik, P.H. (1995) Randomized Placebo-Controlled Phase III Study of Granulocyte-Macrophage Colony-Stimulating Factor in Adult Patients (>55 to 70 Years of Age) With Acute Myelogenous Leukemia: A Study of the Eastern Cooperative Oncology Group (E1490).Blood 86, 457–62.

    PubMed  CAS  Google Scholar 

  16. Stone, R.M., Berg, D.T., George, S.L., Dodge, R.K., Paciucci, P.A., Schulman, P., Lee, E.J., Moore, J.O., Powell, B.L., Schiffer, CA. for Cancer and Leukemia Group B. (1995) Granulocyte-Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia.New Engl. J. Med. 332, 1671–7.

    Article  PubMed  CAS  Google Scholar 

  17. Nemunaitis, J. (1993) Growth Factors in Allogeneic Transplantation.Semin. Oncol. 20, Suppl 6, 96–101.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sandoz Pharma Ltd, Basle, Switzerland

    Rainier Dierdorf

  2. Consult AG, Bern, Switzerland

    Ulrich Kreuter

  3. Clinical Research Consultants, 24 Webergasse, 4058, Basle, Switzerland

    Thomas C. Jones

Authors
  1. Rainier Dierdorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrich Kreuter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas C. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dierdorf, R., Kreuter, U. & Jones, T.C. Use of granulocyte-macrophage colony stimulating factor in the treatment of prolonged haematopoietic dysfunction after chemotherapy alone or chemotherapy plus bone marrow transplantation. Med Oncol 14, 91–98 (1997). https://doi.org/10.1007/BF02990953

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02990953

Keywords

Search

Navigation